“十五五”中医药传承创新有望步入快车道

Investment Rating - The industry rating is maintained at "Overweight" [7][11] Core Insights - The Chinese medicine sector experienced a slight decline of 0.13% last week, with the overall pharmaceutical sector down by 0.22%. The medical device and biological products sectors saw increases of 0.6% and 0.06%, respectively [2][22] - The price-to-earnings (PE) ratio for the Chinese medicine sector is 26.6X, a decrease of 0.04X week-on-week, while the price-to-book (PB) ratio remains stable at 2.24X [3] - The "14th Five-Year Plan" emphasizes the innovation and inheritance of traditional Chinese medicine, positioning it as a strategic emerging industry, which is expected to drive growth in the sector [5] Market Performance - The Chinese medicine sector's performance is relatively stable compared to other pharmaceutical sub-sectors, with notable companies like Wanbangde and Jiaying Pharmaceutical showing strong performance, while companies like Kewang Pharmaceutical and Yue Wannianqing lagged [2][22] - The overall market for Chinese medicinal materials is recovering post-Spring Festival, with a total index of 228.93 points, indicating a stable market despite low activity levels [4] Valuation Metrics - The PE ratio for the Chinese medicine sector is at 26.6X, which is within the 26.82% percentile since 2013, while the PB ratio is at 2.24X, within the 4.63% percentile [3] Policy Impact - Recent policies, including the "14th Five-Year Plan," are expected to significantly influence the Chinese medicine industry in 2026, focusing on value-driven adjustments and innovation [11] - The adjustment of the basic medicine catalog is anticipated to be a major catalyst for the hospital market for Chinese medicine, alongside innovation-driven growth for companies with strong R&D capabilities [11] Investment Recommendations - Focus on companies with evidence of clinical efficacy, strong R&D capabilities, and quality control advantages. Recommended companies include Yiling Pharmaceutical and Zuoli Pharmaceutical, with attention to the recovery of downstream demand for consumer-oriented Chinese medicine [12]